drugset / Trial / NCT05925647
The Effects of Mesenchymal Stem Cell Secretome in Rheumatoid Arthritis Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This research is a clinical trial of administering mesenchymal stem cell secretome to rheumatoid arthritis patients.
Timeline
- Start
- 2022-08-01
- Primary completion
- 2023-02-28
- Completion
- 2023-03-09
Publications
- Results Pratama YS, Pradiptakirana R, Rachmah A, Prabowo NA. Autoimmune Thrombocytopenia in SLE and COVID-19. Eur J Case Rep Intern Med. 2021 Nov 3;8(11):002863. doi: 10.12890/2021_002863. eCollection 2021.
- Results Sholihah MM, Kusuma TRH, Hanif MI, Prabowo NA. Letter to the Editor on Type 1 diabetes onset triggered by COVID-19. Acta Diabetol. 2021 Sep;58(9):1283-1284. doi: 10.1007/s00592-021-01761-3. Epub 2021 Jun 28. No abstract available.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Messenchymal stem cell secretome | Unknown | 1.5 ml | — |